Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.80 |
| ▸ | ADA | P00813 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | AHCY | P23526 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14589609 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15908433 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL474849 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL873738 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10137892 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL11888942 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL939849 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10316549 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL29848577 | 0.90 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL28952403 | 0.90 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012158811-A2 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010091386-A2 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | RFS PHARMA, LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | ADORA2A 84/4885ADA 157/4885ADORA3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.